Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Accounts Payable & Accrued Expense : ¥238.2 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Suzhou Zelgen Biopharmaceuticals Co Accounts Payable & Accrued Expense?

Suzhou Zelgen Biopharmaceuticals Co's quarterly accounts payable & accrued expense increased from Sep. 2023 (¥224.4 Mil) to Dec. 2023 (¥266.1 Mil) but then declined from Dec. 2023 (¥266.1 Mil) to Mar. 2024 (¥238.2 Mil).

Suzhou Zelgen Biopharmaceuticals Co's annual accounts payable & accrued expense increased from Dec. 2021 (¥205.1 Mil) to Dec. 2022 (¥271.7 Mil) but then declined from Dec. 2022 (¥271.7 Mil) to Dec. 2023 (¥266.1 Mil).

Suzhou Zelgen Biopharmaceuticals Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Zelgen Biopharmaceuticals Co Accounts Payable & Accrued Expense Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

90.17

123.21

205.10

271.74

266.14

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															217.61	223.54	224.44	266.14	238.19

Suzhou Zelgen Biopharmaceuticals Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Zelgen Biopharmaceuticals Co Ltd (SHSE:688266) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN

Website

http://www.zelgen.com

Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.

Executives

Zhang Bin	Core technical personnel
Huang Gang	senior management
Lv Bin Hua	Directors, senior managers, core technical personn
Lu Hui Ping	Directors, senior managers
Gao Qing Ping	senior management
Wu Ji Sheng	Directors, senior managers, core technical personn
Zhang Jun Li	senior management
Wu Li Qing	Core technical personnel
	Core technical personnel
Sheng Ze Lin	Directors, senior managers, core technical personn

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Headlines

No Headlines